What is Pacific Biosciences of California Days Payable?
Pacific Biosciences of CaliforniaPACB +3.12%53 Days Payable is 64.45 as of Mar. 2026, which is 28% above its 10-year median of 50.44. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 8 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Pacific Biosciences of California ranks worse than 60.5% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Days Payable Chart
For the Medical Devices subindustry, Pacific Biosciences of California's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Days Payable distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Days Payable falls into.
Pacific Biosciences of California Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a Days Payable of 64.45 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pacific Biosciences of California and its competitors. This is 28% above median its historical median of 50.44. Over the past decade, Pacific Biosciences of California's Days Payable has ranged from 33.46 to 59.69. According to the industry distribution chart, Pacific Biosciences of California ranks #481 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 60.5%.
Is Pacific Biosciences of California's Days Payable too high?
Pacific Biosciences of California's current Days Payable of 64.45 is 28% above median its 10-year median of 50.44. Over the past 10 years, this metric has ranged from a low of 33.46 to a high of 59.69. The Medical Devices & Instruments industry median Days Payable is 67.87. Pacific Biosciences of California's value of 64.45 is 5% below this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #481 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Days Payable compare to CATX and LAB?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #481 out of 795 companies for Days Payable. This places Pacific Biosciences of California in the lower half of its industry. The industry median Days Payable is 67.87. Pacific Biosciences of California's value of 64.45 is 5% below this benchmark. Historically, Pacific Biosciences of California's own Days Payable has ranged from 33.46 to 59.69 over the past decade. While the company's 10-year median is 50.44 vs. the industry median of 67.87, Pacific Biosciences of California has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current Days Payable of 64.45 is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current Days Payable is 64.45, which is 28% above median its own 10-year median of 50.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.65 — trading 1.9% above its estimated fair value. The current Days Payable is 64.45, which is 28% above median its 10-year median of 50.44 and 5% below the Medical Devices & Instruments industry median of 67.87. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Days Payable is 64.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued.
The current stock price of $1.65 is trading 1.9% above its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
Days Payable: 64.45 (28% above median its 10-year median of 50.44)
GF Value™: $1.62 vs. price of $1.65 (1.9% above fair value)
Industry Position: 5% below the Medical Devices & Instruments median (#481 of 795)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
